Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Astellas Pharma, Inc.
- 1,682.50 JPY
- +18.50
- +1.11%
Japan
Nov 16, 2018Ticker
TKS(4503)Prev. close
1,664Market cap (JPY)
3,294.42BMarket cap (USD)
29,053.93MShares
1,979.82M
In the news
- China extends drug patents to 25 years May 16, 2018
- Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018
- Goldman and Nomura lead all-star team behind Takeda-Shire deal May 10, 2018
- Japan's Astellas sees cancer drug fueling 29% profit growth Apr 27, 2018
- Takeda chases global status with $64bn shortcut Apr 26, 2018 See more articles on Astellas Pharma, Inc.
Business Summary
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2018 | JPY | USD |
| Revenue | 1,300.31B | 11,732.27M |
| Gross Profit | 970,228M | 8,754.00M |
| Operating income | 271,241M | 2,447.30M |
| Income before tax | 218,113M | 1,967.95M |
| Net income | 164,679M | 1,485.83M |
| EBITDA | 336,104M | 3,032.54M |
| Diluted EPS | 81.02 | 0.73 |
| Dividends Per Share | 36 | 0.32 |
| Total Assets | 1,858.20B | 17,472.54M |
| Total liabilities | 583,608M | 5,487.61M |
| Total equity | 1,268.28B | 11,925.61M |
| Operating cash flow | 314,463M | 2,837.28M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 1,139.90B | 1,247.25B | 1,372.70B | 1,311.66B | 1,300.31B |
| Gross Profit | 773,281M | 875,398M | 994,723M | 955,325M | 970,228M |
| Operating income | 184,803M | 216,283M | 269,638M | 276,419M | 271,241M |
| Income before tax | 120,524M | 189,466M | 263,013M | 281,769M | 218,113M |
| Net income | 90,874M | 135,856M | 193,687M | 218,701M | 164,679M |
| EBITDA | 249,107M | 281,757M | 338,826M | 340,210M | 336,104M |
| Diluted EPS | 40.39 | 61.40 | 89.62 | 103.55 | 81.02 |
| Dividends Per Share | 27 | 30 | 32 | 34 | 36 |
| Total Assets | 1,653.10B | 1,793.57B | 1,799.33B | 1,814.07B | 1,858.20B |
| Total liabilities | 384,632M | 475,662M | 540,129M | 540,614M | 583,608M |
| Total equity | 1,268.47B | 1,317.91B | 1,259.20B | 1,271.81B | 1,268.28B |
| Operating cash flow | 217,579M | 189,977M | 316,534M | 237,230M | 314,463M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 11,379.57M | 11,353.53M | 11,431.18M | 12,112.80M | 11,732.27M |
| Gross Profit | 7,719.57M | 7,968.55M | 8,283.53M | 8,822.11M | 8,754.00M |
| Operating income | 1,844.86M | 1,968.77M | 2,245.40M | 2,552.63M | 2,447.30M |
| Income before tax | 1,203.17M | 1,724.66M | 2,190.23M | 2,602.04M | 1,967.95M |
| Net income | 907.18M | 1,236.66M | 1,612.92M | 2,019.63M | 1,485.83M |
| EBITDA | 2,486.80M | 2,564.77M | 2,821.56M | 3,141.72M | 3,032.54M |
| Diluted EPS | 0.40 | 0.55 | 0.74 | 0.95 | 0.73 |
| Dividends Per Share | 0.26 | 0.27 | 0.26 | 0.31 | 0.32 |
| Total Assets | 16,051.92M | 14,955.82M | 16,009.05M | 16,279.92M | 17,472.54M |
| Total liabilities | 3,734.83M | 3,966.32M | 4,805.63M | 4,851.60M | 5,487.61M |
| Total equity | 12,317.09M | 10,989.50M | 11,203.42M | 11,413.53M | 11,925.61M |
| Operating cash flow | 2,172.06M | 1,729.31M | 2,635.93M | 2,190.74M | 2,837.28M |
Valuation Measures
| Mar 2018 | |
| PER | 19.89 |
| ROA | 8.96% |
| ROE | 12.96% |
| Operating margin | 20.85% |
| Profit margin | 12.66% |
Key executives
- President, CEO & Representative Director: Kenji Yasukawa
- Chief Financial Officer: Chikashi Takeda
- General Manager-Pharmaceutical Technology: Mitsunori Matsuda
- Executive Officer & Head-Compliance: Fumiaki Sakurai
- Senior Vice President-Corporate Communications: Stig Ogata
Shareholders
- Nomura Asset Management Co., Ltd. (5.0%)
- BlackRock Fund Advisors (4.0%)
- Nippon Life Insurance Co. (3.2%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.9%)
- Astellas Pharma, Inc. (2.9%)
- Nikko Asset Management Co., Ltd. (2.7%)
- BlackRock Japan Co., Ltd. (2.6%)
- The Vanguard Group, Inc. (2.4%)
- Daiwa Asset Management Co. Ltd. (2.2%)
- Norges Bank Investment Management (1.4%)
Contact Details
- Website:http://www.astellas.com
- Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
- Phone: +81.3.3244.3000
Related Companies
- Astellas Pharma, Inc. /Agensys Research Facilities/
- Astellas Pharma, Inc. /16 Long Listed Products/
- Astellas Farma Colombia
- Astellas Pharma Director Incentive Plan
- Astellas Pharma, Inc. /Kiyosu Plant/
- Quethera Ltd.
- PT Astellas Pharma Indonesia
- Astellas Pharma ZAO
- Astellas Pharma ilac Ticaret ve Sanayi AS
- Astellas Pharma Hong Kong Co. Ltd.
- Astellas Pharma India Pvt Ltd.
- Astellas Pharma Thailand Co. Ltd.
- Astellas Pharma Australia Pty Ltd.
- Astellas Pharma Singapore Pte Ltd.
- Astellas Pharma Tech Co., Ltd.
- Mitobridge, Inc.
- Astellas Pharma China, Inc.
- Perseid Therapeutics LLC
- GPDC Partnership
- Astellas Pharma Philippines, Inc.
- Astellas Pharma Co. Ltd.
- Astellas Pharma Canada, Inc.
- Fujisawa Taiwan Co. Ltd.
- Astellas Pharma SARL
- Astellas Pharma Netherlands
- Yamanouchi Health & Beauty Co. Ltd.
- Yabrofarma Lda.
- Fujisawa Ireland Ltd.
- Astellas Pharma Korea, Inc.
- Yamanouchi USA, Inc.
Competitors
- YungShin Global Holding Corp.
- Ipsen SA
- BioLineRX Ltd.
- Coland Holdings Ltd.
- Regeneron Pharmaceuticals, Inc.
- Pieris Pharmaceuticals, Inc.
- Compugen Ltd.
- Agenus Inc.
- Antares Pharma, Inc.
- ImmunoGen, Inc.
- Cidara Therapeutics, Inc.
- Constellation Pharmaceuticals, Inc.
- ESSA Pharma Inc
- Sophiris Bio Inc.
- Urovant Sciences Ltd.
- Matinas BioPharma Holdings, Inc.
- GTx, Inc.
- Mersana Therapeutics, Inc.
- Xenon Pharmaceuticals Inc.
- ArQule, Inc.
- Reata Pharmaceuticals, Inc. Class A
- Kura Oncology, Inc.
- Molecular Templates, Inc.
- Catabasis Pharmaceuticals Inc
- Five Prime Therapeutics, Inc.
- Avadel Pharmaceuticals Plc Sponsored ADR
- Celldex Therapeutics, Inc.
- RedHill Biopharma Ltd.
- Galapagos NV
- Mirati Therapeutics Inc.
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.
Last Updated on 16 Nov, 2018You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
Your full access to the Nikkei Asian Review has expired
